Recent studies indicate that PSMA-PET is not only highly sensitive in the detection of prostate cancer lesions but that change in PSMA uptake under therapy can serve as a marker for treatment response [23,24,25,26]. This evidence concerns the gene FOLH1 and Familial prostate cancer.